Anti-HLA-G Purified

Anti-HLA-G Purified
Regulatory status
RUO
Antigen
HLA-G
Clone
01G
Format
Purified
Reactivity
Human
Variant
0.1 mg
11-438-C100
In stock
170.00 USD

0.025 mg
11-438-C025
Delivery 1 week
85.00 USD
Variant
0.1 mg
11-261-C100
In stock
170.00 USD

0.1 mg
11-261-C100
In stock
85.00 USD
Product details
Description
Images
References
Isotype
Mouse IgG1
Specificity
The antibody 01G recognizes membrane-bound form of HLA-G (full-length HLA-G1), but not soluble forms. HLA-G belongs to the MHC Class I molecules (MHC Class Ib; nonclassical) and it is expressed on the surface of trophoblast cells.
Application details
Flow cytometry: Recommended dilution: 2-4 μg/ml.
Reactivity
Human
Negative species
Mouse, Rat
Immunogen
HLA-B27 transgenic mice were imunized with H-2 identical murine cells transfected with and expressing genes encoding HLA-G and human beta2-microglobulin.
Concentration
1 mg/ml
Preparation
Purified by protein-A affinity chromatography.
Formulation
Phosphate buffered saline (PBS), pH 7.4, 15 mM sodium azide
Storage and handling
Store at 2-8°C. Do not freeze.
Exbio licence note
The product is intended For Research Use Only. Diagnostic or therapeutic applications are strictly forbidden. Products shall not be used for resale or transfer to third parties either as a stand-alone product or as a manufacture component of another product without written consent of EXBIO Praha, a.s. EXBIO Praha, a.s. will not be held responsible for patent infringement or any other violations of intellectual property rights that may occur with the use of the products. Orders for all products are accepted subject to the Term and Conditions available at www.exbio.cz. EXBIO, EXBIO Logo, and all other trademarks are property of EXBIO Praha, a.s.
Antigen description
Human leukocyte antigen G (HLA-G), belonging to MHC class I glycoproteins, plays important roles in both physiological and pathological immunotolerance. It gives an inhibitory signal to cytotoxic T cells, NK cells, monocytes, and some other immune cells. It also induces regulatory T cells and anti-inflammatory macrophages. HLA-G is important e.g. for maternal tolerance to the fetus, and for immunomodulation in particular adult tissues, such as in cornea, pancreatic islets, thymus and other. On the other hand, it is expressed in many solid and hematologic malignancies, where it contributes to evasion of the immune surveillance. HLA-G expression pattern in cancer is an important prognostic factor regarding a poor clinical outcome. Unlike most other MHC glycoproteins, HLA-G acts as an immune checkpoint molecule rather than as an antigen presenting molecule. It concerns both transmembrane and soluble HLA-G isoforms. Among other, HLA-G can promote Th2 immunological response and downregulate Th1 immunological response. For its benefits regarding allograft tolerance, including embryo implantation, soluble HLA-G (sHLA-G) can be used as a marker of developmental potential of embryos during the process of in vitro fertilization. Similarly, sHLA-G concentrations in maternal serum are decreased in preeclampsia. Transplanted patients with increased sHLA-G serum levels have improved allograft acceptance. On the other hand, increased sHLA-G can also indicate presence of malignant (sometimes also of benign) tumor cells. Another important topic is induction of HLA-G expression (sometimes associated with shedding of HLA-G from the cell surface) by some anti-cancer or anti-viral therapies, which can weaken the therapy effect. Monitoring of HLA-G in patients thus has a wide usage.
Entrez Gene ID 3135
UniProt ID P17693
11-438_FC_Profil Značení
Flow cytometry surface staining pattern of HLA-G transfected LCL cells using anti-human HLA-G (01G) purified antibody (concentration in sample 16 μg/ml) GAM APC.
11-438_FC_Histogram
Separation of HLA-G transfected LCL cells (red-filled) from K562 cells (black-dashed) in flow cytometry analysis (surface staining) using anti-human HLA-G (01G) purified antibody (concentration in sample 16 μg/ml) GAM APC.

General references:

Creput C, Durrbach A, Menier C, Guettier C, Samuel D, Dausset J, Charpentier B, Carosella ED, Rouas-Freiss N. Human leukocyte antigen-G (HLA-G) expression in biliary epithelial cells is associated with allograft acceptance in liver-kidney transplantation. J Hepatol. 2003 39(4):587-94.
PubMed
Menier C, Saez B, Horejsi V, Martinozzi S, Krawice-Radanne I, Bruel S, LeDanff C, Reboul M, Hilgert I, Rabreau M, Larrad ML, Pla M, Carosella ED, Rouas-Freiss N: Characterization of monoclonal antibodies recognizing HLA-G or HLA-E: new tools to analyze the expression of nonclassical HLA class I molecules. Hum Immunol. 2003 64(3):315-26.
PubMed
Lin A, Yan WH: Heterogeneity of HLA-G expression in cancers: Facing the challenges. Front Immunol. 2018 Sep 27;9:2164.
PubMed
Hunt JS, Langat DK, McIntire RH, Morales PJ: The role of HLA-G in human pregnancy. Reprod Biol Endocrinol. 2006;4 Suppl 1(Suppl 1):S10.
PubMed
Xu HH, Yan WH, Lin A: The role of HLA-G in human papillomavirus infections and cervical carcinogenesis. Front Immunol. 2020 Jun 25;11:1349.
PubMed
Castelli EC, de Almeida BS, Muniz YC, Silva NS, Passos MR, Souza AS, Page AE, Dyble M, Smith D, Aguileta G, Bertranpetit J, Migliano AB, Duarte YA, Scliar MO, Wang J, Passos-Bueno MR, Naslavsky MS, Zatz M, Mendes CT, Donadi EA: HLA-G genetic diversity and evolutive aspects in worldwide populations. Sci Rep. 2021 Nov 29;11(1):23070.
PubMed
Curigliano G, Criscitiello C, Gelao L, Goldhirsch A: Molecular pathways: Human leukocyte antigen G (HLA-G). Clin Cancer Res. 2013 Oct 15;19(20):5564-71.
PubMed

Product specific references:

Polakova K, Russ G: Expression of the non-classical HLA-G antigen in tumor cell lines is extremely restricted. Neoplasma. 2000;47(6):342-8.
PubMed
Polakova K, Bandzuchova E, Hofmeister V, Weiss EH, Hutter H, Russ G: Binding analysis of HLA-G specific antibodies to hematopoietic cells isolated from leukemia patients. Neoplasma. 2003;50(5):331-8.
PubMed
Polakova K, Krcova M, Kuba D, Russ G: Analysis of HLA-G expression in malignant hematopoetic cells from leukemia patients. Leuk Res. 2003 Jul;27(7):643-8.
PubMed
Wiendl H, Feger U, Mittelbronn M, Jack C, Schreiner B, Stadelmann C, Antel J, Brueck W, Meyermann R, Bar-Or A, Kieseier BC, Weller M: Expression of the immune-tolerogenic major histocompatibility molecule HLA-G in multiple sclerosis: implications for CNS immunity. Brain. 2005 Nov;128(Pt 11):2689-2704.
PubMed
Real LM, Cabrera T, Collado A, Jimenez P, Garcia A, Ruiz-Cabello F, Garrido F: Expression of HLA G in human tumors is not a frequent event. Int J Cancer. 1999 May 17;81(4):512-8.
PubMed
Real LM, Cabrera T, Canton J, Oliva R, Ruiz-Cabello F, Garrido F: Looking for HLA-G expression in human tumours. J Reprod Immunol. 1999 Jul;43(2):263-73.
PubMed
Aractingi S, Briand N, Le Danff C, Viguier M, Bachelez H, Michel L, Dubertret L, Carosella ED: HLA-G and NK receptor are expressed in psoriatic skin: A possible pathway for regulating infiltrating T cells? Am J Pathol. 2001 Jul;159(1):71-7.
PubMed
Variant
0.1 mg
11-438-C100
In stock
170.00 USD

0.025 mg
11-438-C025
Delivery 1 week
85.00 USD
Variant
0.1 mg
11-261-C100
In stock
170.00 USD

0.1 mg
11-261-C100
In stock
85.00 USD

Related products

-134%
Reg. statusCE IVD
ApplicationFC
100 ml
200.00 USD
-134%
Reg. statusCE IVD
ApplicationFC
100 ml
60.00 USD
-134%
Reg. statusRUO
ApplicationFC
100 ml
50.00 USD
-134%
CloneMOPC-21
Reg. statusRUO
0.1 mg
105.00 USD